Eris Lifesciences Limited FY21 Revenues at INR 12,119 mn, up 12.8% YoY

Eris Lifesciences Limited FY21 Revenues at INR 12,119 mn, up 12.8% YoY

Consolidated Financial Highlights:

Particulars

(INR million)

Q4FY21 Q4FY20 YoY(%) FY21 FY20 YoY(%)
Revenue 2,782 2,486 11.9% 12,119 10,741 12.8%
Gross Profit 2,178 2,115 3.0% 9,736 9,025 7.9%
EBITDA 945 772 22.4% 4,306 3,684 16.9%
EBITDA Margin 34.0% 31.1% 290bps 35.5% 34.3% 123bps
PAT 682 563 21.3% 3,551 2,965 19.8%
PAT Margin 24.5% 22.6% 189bps 29.3% 27.6% 170bps

Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd., said, “After significantly outperforming our covered market in FY 21 for the third consecutive year, we witnessed significant outperformance in our Top 3 core therapies in Q1 FY22 on the strength of our predominantly chronic and sub-chronic portfolios. We believe that our focus on building strong brands in fast growing therapies coupled with several patent expiration opportunities will enable us to sustain this growth trajectory.”

Mr. Krishnakumar V, Executive Director & Chief Operating Officer of Eris Lifesciences Ltd., added, “Our focus on building a strong franchise of power brands in cardio-metabolic and VMN continues to drive our growth. Ten out of our Top-15 mother brands are ranked among the Top-5 within their respective segments. We successfully launched 3 new products this quarter – Zomelis SG, Remylin DX and Zac Day. Our latest-generation Diabetes products Zomelis and Gluxit continue to enjoy #1 market ranks and robust growth. We have an exciting period of organic growth coming in the next 4 – 5 years, driven by multiple factors like consolidation of power brands franchise, new launch pipeline, expansion of physician coverage and therapeutic diversification. We continue to look for high-return in-licensing and acquisition opportunities, in order to supplement our organic growth initiatives.”

News Links

Copyright © 2022 Eris Lifesciences Limited. All Rights Reserved.